{"analyses":[{"ciLowerLimit":"0.712","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.277","groupDescription":"Tablet (test) versus Capsule (reference)","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.7707","paramType":"pairwise GMR","paramValue":"0.954","statisticalComment":"1-factor ANOVA of log-transformed, dose-normalized data (factor = formulation)","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.22","value":"18000"}]}],"title":"Capsule"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.28","value":"17200"}]}],"title":"Tablet"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"AUC0-tau was defined as the area under the concentration-time curve from dosing (time 0) of INCB001158 to the end of the dosing period.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors. Participants enrolled in Part 2D received INCB001158 tablets from C1D1 to C1D15, and then switched to INCB001158 capsules starting on C1D16 onwards.","id":"OG000","title":"Part 2D: INCB001158 100 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Tablet: Cycle 1 Day 15 (Tablet) and Cycle 2 Day 1 (Capsule): predose; 0.5, 1, 2, 4, 6, 8, and 10 hours post-dose","title":"AUC0-tau of INCB001158 for Capsules Versus Tablets for Part 2D to Assess the Effect of Formulation","type":"SECONDARY","unitOfMeasure":"hours x ng/mL"}